Bevacizumab
Published date: 2023-04-03 12:27:14
|
Name | Bevacizumab | CAS# | 216974-75-3 |
|---|---|---|---|---|
| Price | $Inquiry/500mg $Inquiry/1g $Inquiry/2g $Inquiry/5g | Purity | 98.0% | |
| Stocking Period |
Inquiry | Stock | In Stock |
| Detail
Product Information
Bevacizumab biosimilar is vascular endothelial growth factor directed antibody. Bevacizumab biosimilar is a recombinant humanized monoclonal IgG1 antibody that contains human framework regions and murine complementarity-determining regions. Bevacizumab biosimilar has an approximate molecular weight of 149 kDa. Bevacizumab is produced in a mammalian cell (Chinese Hamster Ovary) expression system in a nutrient medium. Bevacizumab biosimilar is supplied at a concentration of 25 mg/mL as a sterile, clear to slightly opalescent, colorless to pale brown solution, which contains 60 mg/mL α,α-trehalose dihydrate, 5.8 mg/mL sodium phosphate(monobasic, monohydrate),1.2 mg/mL sodium phosphate(dibasic, anhydrous), 0.4 mg/mL polysorbate 20, and Water for Injection. Statement: this product is used for R&D only, not for clinical usage. |